Àü³²´ëÇб³º´¿ø Á¦124Â÷ È£³²¼øȯ±âÇÐȸ Çмú´ëȸ ¹× ¿¬¼ö°Á : 2019-02-23±³À°ÀÏÀÚ : 2019-02-23
±³À°Àå¼Ò : Á¦ÁÖ´ëÇб³º´¿ø ´ë°´ç
±³À°ÁÖÁ¦ :
Á¦124Â÷ È£³²¼øȯ±âÇÐȸ Çмú´ëȸ ¹× ¿¬¼ö°ÁÂÁÖÃÖ±â°ü : Àü³²´ëÇб³º´¿ø
½ÃÇà±â°ü(ÁöºÎ/°ú) : ½ÉÀå¼¾ÅÍ
´ã´çÀÚ : ±èº¸Àº
¿¬¶ôó : 062-220-6246
À̸ÞÀÏ :
wsboeun@gmail.com ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
Á¦ÁÖƯº°ÀÚÄ¡µµ±³À°½Ã°£ : 8 ½Ã°£ 15ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 02-23 Á¦ÁÖ´ëÇб³º´¿ø ´ë°´ç 08:20~08:30 °³È¸»ç ±æ±¤Ã¤(È£³²¼øȯ±âÇÐȸ ȸÀå)
±³À°½Ã°£ 02-23 Á¦ÁÖ´ëÇб³º´¿ø ´ë°´ç 08:30~09:50 Session I ½ÉÇ÷°üÁúȯÀÇ ÃֽŠÁö°ß 1 Àå°æ½Ä Á¤¸íÈ£(Á¶¼±ÀÇ´ë Àü³²ÀÇ´ë)
±³À°½Ã°£ 02-23 Á¦ÁÖ´ëÇб³º´¿ø ´ë°´ç 08:30~08:45 New guidelines for blood cholesterol management ÇѱâÈÆ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 02-23 Á¦ÁÖ´ëÇб³º´¿ø ´ë°´ç 08:45~09:00 Fish oil and vitamin D use in CV risk reduction ±èÀ̽Ä(ÀüºÏÀÇ´ë)
±³À°½Ã°£ 02-23 Á¦ÁÖ´ëÇб³º´¿ø ´ë°´ç 09:00~09:15 Glucose control in patients with CV disease: SGLT2 inhibitors and beyond °í°üÇ¥(Á¦ÁÖÀÇ´ë)
±³À°½Ã°£ 02-23 Á¦ÁÖ´ëÇб³º´¿ø ´ë°´ç 09:15~09:30 Management of obesity in patients with CV disease ÀÌ°æ¾Ö(ÀüºÏÀÇ´ë)
Åä·Ð 02-23 Á¦ÁÖ´ëÇб³º´¿ø ´ë°´ç 09:30~09:50 ÅäÀÇ ±è±â¼® ±èÁÖÇÑ ¹Ú±ÙÈ£ ¾È¿µ±Ù Á¶ÀåÇö(Á¦ÁÖÀÇ´ë Àü³²ÀÇ´ë Á¶¼±ÀÇ´ë Àü³²ÀÇ´ë ¼øõ¼º°¡·Ñ·Îº´¿ø)
±³À°½Ã°£ 02-23 Á¦ÁÖ´ëÇб³º´¿ø ´ë°´ç 09:50~10:30 Oral Poster Session ±è¼ÛÀÌ Á¤ÁßÈ(Á¦ÁÖÀÇ´ë Á¶¼±ÀÇ´ë)
Åä·Ð 02-23 Á¦ÁÖ´ëÇб³º´¿ø ´ë°´ç 09:50~10:30 ÅäÀÇ ±è°æȯ ±è°èÈÆ ±èÇö¿í ¹ÚÇõÁø ¹üÁ¾¿í ¿À¼º½Ä(¼øõ¼º°¡·Ñ·Îº´¿ø Àü³²ÀÇ´ë ±¤Áֱ⵶º´¿ø Àü³²ÀÇ´ë Á¦ÁÖÀÇ´ë ÀüÁÖ¿¹¼öº´¿ø)
±³À°½Ã°£ 02-23 Á¦ÁÖ´ëÇб³º´¿ø ´ë°´ç 10:30~11:30 Session II ½ÉÇ÷°üÁúȯÀÇ ÃֽŠÁö°ß 2 ¹ÚÁ¾Ãá ÁÖ½ÂÀç(Àü³²ÀÇ´ë Á¦ÁÖÀÇ´ë)
±³À°½Ã°£ 02-23 Á¦ÁÖ´ëÇб³º´¿ø ´ë°´ç 10:30~10:45 Hypertrophic cardiomyopathy: risk stratification & medical management ¼ÛÁöÀº(ÀüÁÖ¿¹¼öº´¿ø)
±³À°½Ã°£ 02-23 Á¦ÁÖ´ëÇб³º´¿ø ´ë°´ç 10:45~11:00 Hypertrophic cardiomyopathy: surgical management Á¤Àμ®(Àü³²ÀÇ´ë)
±³À°½Ã°£ 02-23 Á¦ÁÖ´ëÇб³º´¿ø ´ë°´ç 11:00~11:15 ICD and CRT: guideline vs. reimbursement coverage ±è¼º¼ö(Á¶¼±ÀÇ´ë)
Åä·Ð 02-23 Á¦ÁÖ´ëÇб³º´¿ø ´ë°´ç 11:15~11:35 ÅäÀÇ °µ¿±¸ ±è³²È£ ¿À»ó±â À±ÇöÁÖ È²¼±È£(¸ñÆ÷Áß¾Óº´¿ø ¿ø±¤ÀÇ´ë Àü³²ÀÇ´ë Àü³²ÀÇ´ë ±¤ÁÖº¸Èƺ´¿ø)
±³À°½Ã°£ 02-23 Á¦ÁÖ´ëÇб³º´¿ø ´ë°´ç 11:35~12:40 Session III ½ÉÇ÷°üÁúȯÀÇ ÃֽŠÁö°ß 3 ±æ±¤Ã¤ ¿À¼®±Ô(°¡½¿¶Ù´Â³»°ú ¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 02-23 Á¦ÁÖ´ëÇб³º´¿ø ´ë°´ç 11:35~11:50 Arrhythmias after PCI or cardiac surgery °íÁ¡¼®(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 02-23 Á¦ÁÖ´ëÇб³º´¿ø ´ë°´ç 11:50~12:05 Management of AMI complicating cardiogenic shock ±è¹Îö(Àü³²ÀÇ´ë)
±³À°½Ã°£ 02-23 Á¦ÁÖ´ëÇб³º´¿ø ´ë°´ç 12:05~12:20 Management of VTE in patients with cancer ÀÌÀÚ¿¬(ÀüºÏÀÇ´ë)
Åä·Ð 02-23 Á¦ÁÖ´ëÇб³º´¿ø ´ë°´ç 12:20~12:40 ÅäÀÇ ±èÁØ¿ì À̱âÈ« ÀÌ»óÀç Àü½ÂÁø È«¿µÁØ(¸ñÆ÷Áß¾Óº´¿ø Àü³²ÀÇ´ë ¿ø±¤ÀÇ´ë ±º»êÀÇ·á¿ø Àü³²ÀÇ´ë)
±âŸ 02-23 Á¦ÁÖ´ëÇб³º´¿ø ´ë°´ç 12:40~12:50 ¿ì¼ö±¸¿¬Æ÷½ºÅÍ»ó ½Ã»ó ¹× Æóȸ»ç Á¤¸íÈ£(È£³²¼øȯ±âÇÐȸÀå)